**Participant Information and Consent Form (Symptomatic)**

**Characterizing Antibody Response to Emerging (CARE) COVID-19**

**Principal Investigator**
Dr. Muhammad Morshed, PhD  
Clinical Microbiologist and Program head of Zoonotic Diseases and Emerging Pathogens  
BC Centre for Disease Control  
655 W 12th Ave, Vancouver, BC V5Z 4R4  
Clinical Professor, Department of Pathology and Laboratory Medicine  
University of British Columbia  
2211 Wesbrook Mall, Vancouver, BC V6T 2B5  
Phone: 604-707-2622

**Fraser Health Co-Investigator**
Dr. Shazia Masud, MD, D (ABMM), FRCPC  
Medical Microbiologist, Surrey Memorial Hospital  
13750 96 Ave, Surrey, BC V3V 1Z2  
Clinical Assistant Professor, Department of Pathology and Laboratory Medicine  
University of British Columbia  
Phone: 604-585-5666 ext. 774620  
Pager: 604-450-1582

**Provincial Health Service Authority Co-Investigator**
Dr. David Goldfarb  
Medical Microbiologist, BC Children's Hospital  
4500 Oak St, Vancouver, BC V6H 3N1  
Clinical Associate Professor, Department of Pathology and Laboratory Medicine  
University of British Columbia  
Phone: 604-875-2345 ext. 7688

**Providence Health Care Co-Investigator**
Dr. Victor Leung  
Medical Director, Infection Prevention and Control, St. Paul’s Hospital  
1081 Burrard St, Vancouver, BC, V6Z 1Y6  
Clinical Associate Professor, Department of Pathology and Laboratory Medicine  
University of British Columbia  
Phone: 604-682-2344, ext. 69373

**1. Invitation**

You are being invited to take part in this research study, because you are a healthcare worker or other individual who has developed symptoms suggesting you may have COVID-19. The purpose of this study is to learn more about the antibody-specific immune response to COVID-19 in healthcare workers and others in British Columbia.
2. Your participation is voluntary

Your participation is voluntary. You have the right to refuse to participate in this study. If you decide to participate, you may still choose to withdraw from the study at any time without any negative consequences to the medical care, education, or other services to which you are entitled or are presently receiving.

Please review the consent document carefully when deciding whether or not you wish to be part of the research and sign this consent only if you accept being a research participant.

3. Who is conducting this study?

This study is being conducted by researchers affiliated with The University of British Columbia, The BC Centre for Disease Control, Vancouver Coastal Health Authority, Providence Health Care and Fraser Health. The study is funded in part by Genome BC Rapid Response Funding and the BC Centre for Disease Control.

4. Background

Most of what we know about the spread of COVID-19 (Coronavirus Disease 2019) around the world has been learned using laboratory tests that look directly at the virus’s genetic material called ‘RNA’. When someone is suspected of having COVID-19, a sample is taken from deep inside the nose using a swab. If virus RNA is found on the swab, we assume that person is infected and contagious. Once a person gets better and that virus is cleared, we will no longer be able to see the virus using these tests. Fortunately, virus infections leave behind a signature in the blood called ‘virus-specific antibodies’ that can be detected using antibody tests – we also call these serological tests.

We can learn a lot about a disease by looking at the antibodies in someone’s blood. First, we can learn if someone has been infected with a virus just by looking at the antibodies long after the virus itself has been cleared. We can also learn about what stage of infection someone is in by looking at the different types of antibodies, for example some antibodies are only seen at the beginning of infection while others will be detectable for years or even decades. We can also use antibody tests to measure what level of the population is immune to a virus by screening how many people have antibodies. But first, we have to be confident that the antibody response is effective, because some viruses have ways of escaping or hiding from antibodies. We still don’t know enough about COVID-19 to understand how effective our antibody response is to the virus.

In this study we are recruiting 900 individuals that have just begun to feel sick and suspect they have COVID-19, but have not yet been diagnosed. This is the perfect opportunity for us to look at how your body’s immune response is developing and how the level of virus in your body changes with the appearance of these antibodies. This information will be important for further understanding how quickly healthcare workers and other individuals develop an immune response to COVID-19.
5. What is the purpose of the study?

The purpose of this study is to learn more about how the immune system responds to and is sustained in healthcare workers and others who contract COVID-19. We will monitor the antibody immune response and the presence of the virus for three months to determine how quickly antibodies are made, how long they last and how this correlates with the absence or appearance of virus RNA over time.

6. Who can participate in this study?

You may be able to participate in this study if:

- You have recently started to feel ill and suspect that you have COVID-19 infection
- You are over 18 years of age and are able to provide informed consent

7. What does the study involve?

**Study Visits**

If you agree to take part in this study, you will be asked to donate 10 ml (2 teaspoons) of blood and respiratory samples at up to 6 separate visits over 3 months. At this time, nasopharyngeal (back of the nose) swabs will be collected when you are being initially tested for COVID-19 (baseline visit). If you are diagnosed COVID-19 positive, you will be provided with materials to self-collect a saliva sample at each follow-up visit. A saliva self-collection kit can be mailed to you if you provide a mailing address at the end of this form or you will be given the option of collecting a kit from one of the study sites. Each sample collection visit will only require 10-15 minutes of your time (excluding travel time). Your samples will be stored securely at the BC Centre for Disease Control.

These visits include:

1. Baseline visit (as soon as possible when you start to feel ill). If your baseline test is positive for COVID-19 we will ask you to also donate blood and respiratory samples at up to five additional visits.
2. 7 days after symptom onset (this time-point collection is only available for individuals presenting to the PHSA Children’s Hospital collection site)
3. 10 days after symptom onset or when you are clear to leave isolation
4. 14 days after symptom onset
5. 30 days after symptom onset
6. 3 months after symptom onset

**Medical Information**

Your samples and test results will be linked to medical information collected in relation to your diagnosis of COVID-19 including your COVID-19 test results, symptoms, symptom onset and severity, level of care required, health authority, if your infection is travel or community acquired, healthcare worker category, as well as your age and sex.
If you have previously participated in a COVID-19 antibody study this year at BC Children’s Hospital, we are also asking you to consent to having these antibody test results shared with the researchers of the CARE study for comparison of results between studies.

In addition to accessing medical records related to COVID-19 we are also asking you to fill out a brief checklist of symptoms you experience and the day of their onset at the time of each sample donation. These symptoms will be linked to your antibody and virus test results. Filling out this checklist is optional and you do not have to provide this additional information if you are not comfortable doing so.

**Future Studies**

You will be asked if you give us permission to use any of the samples you provide for future COVID-19 related studies. You are free to say yes or no to having your samples used in other research and this will not affect your participation in this study. If you give consent, any sample remaining at the end of this study will be assigned an anonymous, unique code number that will allow your samples to be used anonymously in future research. If you do not allow this, any remaining sample will be destroyed at the end of this study.

If you attend the PHSA collection site at Children’s Hospital for your sample collection, there is an opportunity to donate additional blood for future research. Blood would be collected at the same time as your study blood collection and we would not collect more than 30 ml of blood (2 tablespoons) in total. These extra samples will be kept in the BC Children's Hospital BioBank, which acts as a biological library of samples for future research. Your sample will not be made available for other research until this has been discussed with you in more detail and you agree.

**Follow-up**

As part of your standard medical care, you will be informed if you are diagnosed with COVID-19 whether you decide to participate in this study or not. You may also be informed of your antibody response to this virus if you choose to be contacted with these results. At the end of this form you will be asked to provide a mailing address, which will be used to mail a paper copy of the results to you.

### 8. What are the possible harms and discomforts?

The research study requires the collection of blood samples; the risks of blood draw include mild pain or discomfort and bruising and the rare possibility of infection. For COVID-19 diagnosis you will also need to submit a nasopharyngeal swab, which collects a sample from the back of the nose. You may gag a little during the test, or feel slightly uncomfortable, and there is a possibility you may have a minor nosebleed afterwards.

### 9. What are the potential benefits of participating?

There may not be a direct benefit to you from taking part in this study. However, a potential benefit is that you may be identified as having developed an antibody response to COVID-19. You will also be aiding the BC Centre for Disease Control to validate
screening procedures for antibody responses to COVID-19 and aid in understanding the immune response to SARS-CoV-2 (the virus that causes COVID-19) infection. This may be of indirect benefit to you because the information will be used to guide the public health response to COVID-19 and may be used to identify healthcare workers with immunity that can become the main task force attending the COVID-19 crisis.

10. What happens if I decide to withdraw my consent to participate?

You may withdraw from this study at any time without giving reasons. If you choose to enter the study and then decide to withdraw at a later time, you have the right to request the withdrawal of your information and/or samples collected during the study. This request will be respected to the extent possible. Please note however that there may be exceptions where the data will not be able to be withdrawn for example where the data is no longer identifiable (meaning it cannot be linked in any way back to your identity) or where the data has been merged with other data. If you would like to request the withdrawal of your data and/or samples, please contact the Principal Investigator of this project.

11. How will my taking part in this study be kept confidential?

Your confidentiality will be respected. However, research records and health or other source records identifying you may be inspected in the presence of the Investigator, or his or her designate, by representatives of The BC Centre for Disease Control, Health Canada, or the UBC Clinical Research Ethics Board for the purpose of monitoring the research. No information or records that disclose your identity will be published without your consent, nor will any information or records that disclose your identity be removed or released without your consent unless required by law.

You will be assigned a unique study number as a participant in this study. This number will not include any personal information that could identify you (e.g., it will not include your Personal Health Number, SIN, or your initials, etc.). Only this number will be used on any research-related information collected about you during the course of this study, so that your identity will be kept confidential. Information that contains your identity will remain only with the Principal Investigator, Medical Health Officer or other Medical or Laboratory personal who have routine access to medical information and protect patient confidentiality as a condition of employment. The list that matches your name to the unique study number that is used on your research-related information will not be removed or released without your consent unless required by law.

Your rights to privacy are legally protected by federal and provincial laws that require safeguards to ensure that your privacy is respected. You also have the legal right of access to the information about you and, if need be, an opportunity to correct any errors in this information. Further details about these laws are available on request to the Principal Investigator of this study. Your personal information or information that could identify you will not be revealed without your express consent unless required by law.
12. What will the study cost me?

The research-related blood draws and respiratory sample collection required for your participation in this study will be provided at no cost to you, however you will be required to arrange transportation to and from sample collection sites. Participants diagnosed with COVID-19 who are eligible for 3 months follow up will receive a $50 gift card, while those who are COVID-19 negative will receive a $10 gift card as a token of our appreciation for participating in the study. In the long-term, if a research, diagnostic or therapeutic product or service is developed, you will not receive a financial benefit.

13. Who do I contact if I have questions about the study during my participation?

If you have any questions or desire further information about this study before or during participation you can contact the Principal Investigator of this project, Dr. Muhammad Morshed at (604) 707-2622 or contact the study team at CAREstudy@bccdc.ca.

14. Who do I contact if I have any questions or concerns about my rights as a participant?

If you have any concerns or complaints about your rights as a research participant and/or your experiences while participating in this study, contact the Research Participant Complaint Line in the University of British Columbia Office of Research Ethics by e-mail at RSIL@ors.ubc.ca or by phone at 604-822-8598 (Toll Free: 1-877-822-8598). For Fraser Health Participant concerns please contact the Fraser Health Research Ethics Board Co-Chair at 604-587-4681. Please reference the study number H20-01089 when calling so the Complaint Line staff can better assist you.

15. After the study is finished

Regardless of the study outcomes or your decision to participate, you will be informed of your COVID-19 status determined using the current standard of care (viral RNA testing on your first nasopharyngeal swab) as soon as the results are available. Your physician or a medical health officer will report this result to you directly. Your clinical test results will also be available online using e-health if you have a registered account.

If you choose to be contacted regarding your antibody testing results and provide a valid mailing address, you will receive a paper copy of your antibody testing results once the antibody testing strategies are rigorously evaluated and public health officials approve of releasing these results to individuals.
16. Participant Consent: Characterizing Antibody Response to Emerging (CARE) COVID-19

My signature on this consent form means:

- I have read and understood the information in this consent form.
- I have had enough time to think about the information provided.
- I have been able to ask for advice if needed.
- I have been able to ask questions and have had satisfactory responses to my questions.
- I authorize access to my health records related to COVID-19 as described in this consent form.
- I understand that my participation in this study is voluntary.
- I understand that I am completely free at any time to refuse to participate or to withdraw from this study at any time, and that this will not change the quality of care that I receive.
- I understand that I am not waiving any of my legal rights as a result of signing this consent form.
- I will receive a signed copy of this consent form for my own records.

I consent to participate in this study: □ Yes  □ No

I consent to sharing previous COVID-19 antibody study results with the CARE study team: □ Yes  □ No  □ N/A

I agree that any leftover blood samples can be used for future COVID-19 related research.

I recognize that I can withdraw any remaining blood or swab samples at a later date and request that these be destroyed: □ Yes  □ No

I agree to have additional blood collected for future research and agree to be contacted by BC Children’s Hospital BioBank to discuss use of these samples: □ Yes  □ No  □ N/A

I agree to have a paper copy of my COVID-19 serology results mailed to me: □ Yes  □ No

Mailing address: _____________________________________________________________

<table>
<thead>
<tr>
<th>Street</th>
<th>City</th>
<th>Province</th>
<th>Postal code</th>
</tr>
</thead>
</table>

I agree to be contacted in future about related research studies that may be of interest to me. I recognize that I can choose not to participate in future research studies: □ Yes  □ No

Contact e-mail: ________________  Optional Phone Number________________

*This email will only be used to contact you regarding this study (e.g. consent confirmation, sample collection reminders, study updates) and if you indicated yes above to be contacted regarding future studies. You need to know that emails sent to some webmail services (e.g. Gmail, Hotmail, etc.), may be stored/routed outside of Canada (for example, in the United States) and governed by foreign laws. Due to the fact that future emails will contain personal information about you, including your name and information about your health, the Freedom of Information and Protection of Privacy Act requires that we obtain your consent before we continue. All of the information which you provide to us will be kept completely confidential. Providing your email address means that you voluntarily agree and give your consent for the study team to use email to communicate with you.
Participants Signature

<table>
<thead>
<tr>
<th>Participant’s Signature</th>
<th>Printed name</th>
<th>Date</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Signature of Person Obtaining Consent</th>
<th>Printed name</th>
<th>Study Role</th>
<th>Date</th>
</tr>
</thead>
</table>

Investigator Signature

<table>
<thead>
<tr>
<th>Investigator Signature</th>
<th>Printed name</th>
<th>Date</th>
</tr>
</thead>
</table>

My signature above signifies that the study has been reviewed with the study participant by me and/or by my delegated staff. My signature may have been added at a later date, as I may not have been present at the time the participant’s signature was obtained.